Edgen AI operates independently of, and is not controlled by Aspen Digital Financial Limited.
Amazon brings xAI's Grok 4.3 to Bedrock as 3-model AI war escalates
Edgen Stock·Jul 16 2026, 21:14Share to
Share to
Copy link
[1] Amazon integrates xAI's Grok 4.3 on Bedrock, intensifying the enterprise AI arms race (https://cryptobriefing.com/amazon-grok-bedroc ...)[2] UAE Gets License-Free Nvidia AI Chips as Congress Probes Trump Crypto Conflict (https://www.msn.com/en-us/money/markets/uae-g ...)[3] Amazon adds Elon Musk's Grok 4.3 AI model to Be... - Pluang (https://pluang.com/en/news-feed/amazon-integr ...)[4] Kimi K3 by Moonshot AI ranks No. 1 in Frontend Code Arena, dethroning Claude and GPT - Crypto Briefing (https://cryptobriefing.com/kimi-k3-moonshot-a ...)
Related News
Jul 16 2026, 21:30
Jasper Therapeutics merges with Kira in $132M biotech deal
Jasper Therapeutics Inc. completed its all-stock acquisition of Kira Pharmaceuticals and raised $132 million in a concurrent private placement, creating a combined company with three clinical-stage immunology assets and cash runway through the second half of 2028. "The quality of their science and the deep expertise of their team" drove the decision to merge, Jeet Mahal, president and chief executive officer of Jasper, said in a statement. The combined entity will focus on advancing KP-104, a dual-complement inhibitor for paroxysmal nocturnal hemoglobinuria and renal disorders, alongside briquilimab, an anti-KIT antibody for severe combined immunodeficiency, and KP-701, a preclinical B-cell receptor targeted therapy. The private placement was co-led by Affinity Asset Advisors and Ikarian Capital, with participation from Columbia Threadneedle Investments, Sirenia Capital Management, Balyasny Asset Management, and Mirador Therapeutics, among others. Pro-forma cash is expected to fund operations through multiple clinical milestones, including KP-104 Phase 2 interim data in the fourth quarter of 2026 and an end-of-Phase 2 meeting with the FDA for PNH in the first half of 2027. The deal structure gives pre-merger Jasper equity holders about 6.68% of the combined company's common stock, Kira holders about 49.86%, and PIPE investors about 43.46%, on a fully diluted as-converted basis. Existing Jasper shareholders also received a contingent value right worth $30 million tied to a priority review voucher for briquilimab by December 2028. Kira out-licensed two earlier-stage assets — KP-301 and KP-402 — to Mirador Therapeutics for $12 million upfront plus development and sales milestones, allowing the combined company to concentrate resources on its lead programs. **KP-104 Leads the Pipeline** KP-104, also known as Vensobafusp alfa, is a bifunctional biologic that targets both the alternative and terminal complement pathways simultaneously, a dual mechanism that differentiates it from single-pathway inhibitors such as Alexion's Soliris and Ultomiris. The drug is Phase 2/3 ready and has already generated positive data in treatment-naive PNH patients. The combined company plans to report interim data from Stage 1 of a Phase 2 basket trial in rare renal indications in the fourth quarter of 2026, with updated data in the second quarter of 2027. A new indication for KP-104 will be announced by the end of this year. Briquilimab, a late-stage anti-KIT antibody, is advancing toward a pre-BLA meeting with the FDA for SCID in the first quarter of 2027. The drug blocks stem cell factor from binding to the KIT receptor, inhibiting survival signals for mast cells and hematopoietic stem cells. The company is also evaluating the mast-cell mediated disease landscape and plans to provide an update on clinical development in the second half of 2026. KP-701, a novel dual-acting anti-CD79BxCD32B monoclonal antibody for autoantibody-mediated disorders, is expected to enter Phase 1 testing in the first quarter of 2027, with first-in-human data anticipated in the third quarter. **Cash Runway and Investor Implications** The combined company holds enough capital to reach key value-inflection points without near-term dilution risk, a critical factor for biotech investors evaluating early-stage pipelines. Jasper shares trade on Nasdaq under the ticker JSPR. The company did not disclose post-merger cash balance but said the $132 million private placement, combined with existing cash and the $12 million upfront from the Mirador out-licensing, funds operations through the second half of 2028. This article is for informational purposes only and does not constitute investment advice.
Jul 16 2026, 21:27
Citi says pharma index beats S&P 500, flags biopharma haven
Citi analysts named biopharma stocks a defensive haven in a July 16 research note. The call comes as the NYSE Arca Pharmaceutical Index has outperformed the S&P 500 over the past month, reflecting investor demand for stable earnings and pricing power. The sector's resilient earnings profile and pricing power make it an attractive hedge against broader market volatility, the bank's research team said in a note dated July 16. Citi's analysts highlighted the defensive characteristics of large-cap pharmaceutical companies, which tend to generate consistent cash flows regardless of the economic cycle. The NYSE Arca Pharmaceutical Index has outpaced the broader market as investors seek sectors with less cyclical exposure. The S&P 500 has faced headwinds from uncertainty over interest rates and economic growth, driving capital toward defensive industries. Healthcare has historically been one of the best-performing sectors during periods of market stress, with pharmaceutical companies offering both dividend income and earnings visibility. The call could accelerate capital rotation into healthcare, a sector that has lagged the technology-driven rally for much of the past two years. Biopharma stocks offer a combination of dividend income and earnings visibility that becomes more attractive as macroeconomic uncertainty persists. Citi's endorsement adds institutional credibility to the trade, potentially pushing the NYSE Arca Pharmaceutical Index higher relative to the broader market in the near term. For holders, the Citi note reinforces the case for healthcare as a portfolio hedge against broader market weakness. Investors will watch upcoming earnings reports from major pharmaceutical companies, including Merck and Eli Lilly, for confirmation of the defensive thesis. This article is for informational purposes only and does not constitute investment advice.
Jul 16 2026, 21:27
US strikes supertanker near Iran's Kharg Island as blockade widens
**The US military's first attack on a vessel inside the Persian Gulf since reimposing its blockade signals a significant escalation in the campaign to cut off Iran's oil revenue.** The US Central Command said an American aircraft fired missiles at the unladen and US-sanctioned supertanker Belma early Thursday after the vessel repeatedly ignored warnings that it was violating the blockade by sailing through international waters toward Kharg Island, Iran's primary crude export terminal. The strike deep inside the Persian Gulf, far from the Strait of Hormuz, marks a departure from the initial blockade that focused on intercepting vessels attempting to cross an American-imposed line beyond the waterway in the Gulf of Oman. "While this is new in terms of the implementation occurring within the gulf, it's still consistent with their stated goal of blockading all Iranian ports and coastal areas," said Jennifer Parker, an adjunct professor at the University of Western Australia Defence and Security Institute. Ship-tracking data showed the Belma sailing north toward Kharg late Wednesday before making a sharp turn away after being hit. Centcom said it had redirected two compliant commercial vessels and disabled one non-compliant ship in the first 24 hours of the renewed blockade, which took effect at 4 p.m. Washington time on Tuesday. The strike comes after the US reimposed its maritime blockade on July 14, following a three-week interim peace deal that had temporarily eased restrictions. The escalation is already reshaping oil markets and shipping patterns. Spot prices for Middle Eastern crude rose this week, with the market shifting into backwardation — where front-month contracts trade above deferred contracts — signaling supply tightness. Tanker traffic through the Strait of Hormuz collapsed on Sunday, with only six vessels completing the transit, all operating with their Automatic Identification System transponders disabled, according to preliminary data from Kpler. By Monday morning, no ships were observed transiting based on AIS signals. **Shadow Fleet and Covert Operations** Satellite imagery from the EU Copernicus program shows at least four oil tankers with transponders turned off conducting ship-to-ship cargo transfers near Fujairah Port in the UAE and Sohar Port in Oman, suggesting covert passage operations as vessels seek to avoid detection and evade sanctions. Maritime intelligence firm Windward identified 23 Iranian-flagged vessels operating within the Strait of Hormuz that are flying false flags, disabling AIS transponders, or otherwise disguising their activities. Of those, 10 are loaded with cargo while 13 are empty, according to cargo tracking service Vortexa. Iran has a long track record of evading sanctions through complex networks of shell companies and clandestine crude transfers, said Adnan Mazarei, a senior fellow at the Peterson Institute for International Economics and former deputy director of the International Monetary Fund. TankerTrackers data shows Iran exported approximately 50 million barrels of crude in June and 10 million barrels in a single day last week, even during the period when Iranian crude was temporarily exempt from sanctions under the now-expired memorandum of understanding. Seven fully laden giant tankers that transited the strait during the ceasefire are now waiting in the Indian Ocean for buyers, according to Windward. **Market and Economic Fallout** The Strait of Hormuz handles about 21% of global oil trade, making any sustained disruption a direct threat to energy markets. The head of the International Energy Agency warned that the global economy might once again be in peril if the conflict choking the strait is not resolved within weeks. Qatar's Transport Ministry issued an urgent advisory suspending all maritime vessel activity until further notice — the first blanket maritime suspension by a Gulf state since the conflict began, according to Windward. Goldman Sachs said in a July 15 report that even after geopolitical tensions ease, the next phase of Persian Gulf shipping recovery could be slower than the initial phase, noting that cargo flows through Omani and international shipping lanes have plunged following recent tanker attacks. The US Navy said it would allow shipments of bulk food, medical supplies, and other goods necessary to the survival of Iran's civilian population through the blockade after vetting vessel requests. Iran relies on oil sales for approximately 50% of its revenue, and China imports roughly 80% of Iranian crude despite US sanctions, according to the US Energy Information Administration. The initial blockade drove Iran's inflation rate to 50% over the past 12 months — the highest since World War II — with food inflation running above 100%. With roughly 90% of Iran's trade passing through the Persian Gulf, a prolonged blockade would deepen the economic toll significantly. This article is for informational purposes only and does not constitute investment advice.